目的 探討鹽酸川芎嗪注射液聯(lián)合阿司匹林和阿托伐他汀治療冠心病心絞痛的臨床療效。方法 選取2014年10月—2016年1月延安大學(xué)附屬醫(yī)院收治的冠心病心絞痛患者126例，隨機分為對照組（63例）和治療組（63例）。對照組在一般治療基礎(chǔ)上口服阿司匹林腸溶片，1片/次，1次/d；同時晚餐口服阿托伐他汀鈣片，1片/次，1次/d。治療組患者在對照組的基礎(chǔ)上靜脈滴注鹽酸川芎嗪注射液，2 mL加入生理鹽水300 mL中，1次/d。兩組患者治療時間均為15 d。治療后觀察兩組患者綜合療效和心電圖療效。比較兩組患者每天心絞痛的發(fā)作次數(shù)與發(fā)作持續(xù)時間，兩組患者總膽固醇（TC）、三酰甘油（TG）和低密度脂蛋白膽固醇（LDL-C）等血脂指標(biāo)，以及腫瘤壞死因子-α（TNF-α）、白細(xì)胞介素-6（IL-6）、巨噬細(xì)胞移動抑制因子（MIF）、高遷移率族蛋白B1（HMGB1）及超敏C反應(yīng)蛋白（hs-CRP）等炎性因子水平。結(jié)果 治療后，對照組和治療組的綜合總有效率分別為85.71%、95.24%，兩組比較差異有統(tǒng)計學(xué)意義（P < 0.05）。治療后，對照組和治療組心電圖總有效率分別為76.19%、87.30%，兩組比較差異有統(tǒng)計學(xué)意義（P < 0.05）。治療后，治療組患者每天心絞痛發(fā)作次數(shù)及心絞痛持續(xù)時間均明顯少于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P < 0.05）。治療后，兩組患者血清TC、TG和LDL-C的量均明顯降低（P < 0.05）；且治療后治療組上述指標(biāo)水平均明顯低于對照組（P < 0.05）。治療后，兩組患者TNF-α、IL-6、MIF、HMGB1和hs-CRP含量均明顯低于治療前（P < 0.05）；且治療后治療組患者炎性因子水平顯著優(yōu)于對照組（P < 0.05）。結(jié)論 鹽酸川芎嗪注射液聯(lián)合阿司匹林和阿托伐他汀治療冠心病心絞痛臨床療效較好，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical effect of Ligustrazine Hydrochloride Injection combined with aspirin and atorvastatin in treatment of coronary heart disease with angina pectoris. Methods Patients (126 cases) with coronary heart disease with angina pectoris in Yan'an University Affiliated Hospital from October 2014 to January 2016 were randomly divided into control (63 cases) and treatment (63 cases) groups. Patients in the control group were po administered with Aspirin Enteric-coated Tablets, 1 tablet/time, once daily. And they were also po administered with Atorvastatin Calcium Tablets at dinner, 1 tablet/time, once daily. Patients in the treatment group were iv administered with Ligustrazine Hydrochloride Injection on the basis of the control group, 2 mL added into normal saline 300 mL, once daily. Patients in two groups were treated for 15 d. After treatment, the comprehensive clinical efficacy and electrocardiogram efficacy were observed, the frequency and duration of angina pectoris, TC, TG, LDL-C, TNF-α, IL-6, MIF, HMGB1, and hs-CRP levels in two groups were compared. Results After treatment, the comprehensive clinical efficacies in the control and treatment groups were 85.71% and 95.24% respectively, and there was difference between two groups (P < 0.05). After treatment, the electrocardiogram efficacies in the control and treatment groups were 76.19% and 87.30% respectively, and there was difference between two groups (P < 0.05). After treatment, the frequency and duration of angina pectoris in the treatment group were significantly less than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the TC, TG, and LDL-C levels in two groups were significantly decreased (P < 0.05). And these blood lipid indexes levels in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the TNF-α, IL-6, MIF, HMGB1, and hs-CRP in two groups significantly decreased (P < 0.05). And these inflammatory factors levels in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Ligustrazine Hydrochloride Injection combined with aspirin and atorvastatin has a good clinical effect in treatment of coronary heart disease with angina pectoris, which has a certain clinical application value.